All In Biotech

BLA 125433 · Janssen Biotech

Simponi Aria

Golimumab · Injection · Tumor Necrosis Factor Blocker

Orphan

Last checked: Nov 20, 2026Latest source record: Apr 18, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2013

Jul 18, 2013

Approved uses

7

Original approval plus efficacy supplements

Registered trials

110

40 Phase 3, 8 recruiting

FAERS reports

12,593

9,544 serious, 2,708 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: SERIOUS INFECTIONS and MALIGNANCY WARNING: SERIOUS INFECTIONS and MALIGNANCY See full prescribing information for complete boxed warning. Serious infections leading to hospitalization or death including tuberculosis (TB), bacterial sepsis, invasive fungal (such as histoplasmosis), and other opportunistic infections have occurred in patients receiving SIMPONI ARIA ( 5.1 ). Discontinue SIMPONI ARIA if a patient develops a serious infection or sepsis ( 5.1 ). Perform test for latent TB; if positive, start treatment for TB prior to starting SIMPONI ARIA ( 5.1 ). Monitor all patients for active TB during treatment, even if initial latent TB test is negative ( 5.1 ). Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers, of which SIMPONI ARIA is a member ( 5.2 ). SERIOUS INFECTIONS Patients treated with SIMPONI...

What it is approved for

From the label in effect Sep 9, 2025.

SIMPONI ARIA is a tumor necrosis factor (TNF) blocker indicated for the treatment of: Adult patients with moderately to severely active Rheumatoid Arthritis (RA) in combination with methotrexate ( 1.1 ) Active Psoriatic Arthritis (PsA) in patients 2 years of age and older ( 1.2 ) Adult patients with active Ankylosing Spondylitis (AS) ( 1.3 ) Active polyarticular Juvenile Idiopathic Arthritis (pJIA) in patients 2 years of age and older ( 1.4 ) 1.1 Rheumatoid Arthritis (RA) SIMPONI ARIA, in combination with methotrexate (MTX), is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis. 1.2 Psoriatic Arthritis (PsA) SIMPONI ARIA is indicated for the treatment of active psoriatic arthritis in patients 2 years of age and older. 1.3 Ankylosing Spondylitis (AS) SIMPONI ARIA is indicated for the treatment of adult patients with active ankylosing spondylitis. 1.4 Polyarticular Juvenile Idiopathic Arthritis (pJIA) SIMPONI ARIA is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients 2 years of age and older.

Mechanism: Golimumab is a human monoclonal antibody that binds to both the soluble and transmembrane bioactive forms of human TNFα. This interaction prevents the binding of TNFα to its receptors, thereby inhibiting the biological activity of TNFα (a cytokine protein). There was no evidence of the golimumab antibody binding to other TNF superfamily ligands; in particular, the golimumab antibody did not bind or neutralize human lymphotoxin. Golimumab did not lyse human monocytes expressing transmembrane TNF in the presence of complement or effector cells. Elevated TNFα levels in the blood, synovium, and...

Therapeutic areas: Oncology

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

1 products under this application
  • SIMPONI ARIA · GOLIMUMAB 50MG/4ML · INJECTABLE, INJECTION · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Golimumab" as an intervention, any sponsor and status, largest first.

All 110 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective3,916
  • off label use2,949
  • pain2,949
  • rheumatoid arthritis2,927
  • fatigue2,768
  • alopecia2,587
  • rash2,513
  • systemic lupus erythematosus2,509
  • abdominal discomfort2,482
  • pemphigus2,476
  • glossodynia2,470
  • hypersensitivity2,434

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2009124
2010170
2011304
2012243
2013200
2014124
2015594
2016405
2017590
2018752
2019768
2020775
20211,050
20221,243
20231,034
20241,785
20251,676
2026756

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Simponi Aria (Golimumab)

2024 spending

$45.9M

Beneficiaries

1,596

6,219 claims

Per beneficiary

$28,755

$488.73 per unit

View as table
YearSpending
2020$17,925,046
2021$23,709,395
2022$30,867,534
2023$38,842,776
2024$45,893,236

Part B: Simponi Aria (Golimumab) · HCPCS J1602

2024 spending

$330M

Beneficiaries

33,452

161,396 claims

Per beneficiary

$9,865

2024 ASP limit $11.65 per unit

View as table
YearSpending
2020$359,695,134
2021$370,063,975
2022$374,047,499
2023$364,677,329
2024$329,994,823

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 388 on PubMed

Sponsor: Johnson & Johnson (Janssen)

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.